This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.
The company will address as many questions as possible, and focus on those questions most wanted by investors.
Can you disclose a timline for the start of Phase 3 in Prostate and Glioblastoma?
In the presentation at Økonomisk Uge Brev in june 2023, there was a question about the liquidity of the stock. Management said that they might look into either a move to nasdaq in Sweden or possibly a dual listing?
Is there any new information about this?
Previously in 2023 you have mentioned that you are looking on how to secure funding for next year, in the second half of this year. How is it going with that work and are you in talks with larger investors as well?
What do you expect the Stock value is in the end of 2024
What are your plans for the indications in Lungcancer and Breastcancer?
When do you expect the first payment from Curium?
RedEye talks about another phase2 trial in prostate cancer before moving to phase 3 - could you touch on this please?
Please tell us what the status og the phase III study in prostate cancer is.
Could you talk a bit about the posibility of expanding the current pipeline? Considering results in both breast and lung cancer.
How long will patients need to be follow for uTreat?
How long will you need to follow patients for uTreat?
Do you plan for a combined study in Glioblastoma with both Utrace and Utreat and also same partner to support both Utrace and Utreat? And if so could this also be a strategy in other indications with a partner who covers both Utrace and Utreat in same indications?
Are you satsifed with the coverage from SEB?
Any plans of additional coverage from other major investment banks?